BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Bergen, Norway, 6[th] March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021. The presentation was led by BerGenBio’s scientific collaborator, Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa City, USA), who presented preclinical data. The